| 1. |
- Mizuki, T., et al.
(författare)
-
Orbital Characterization of GJ1108A System, and Comparison of Dynamical Mass with Model-derived Mass for Resolved Binaries
- 2018
-
Ingår i: Astrophysical Journal. - : American Astronomical Society. - 0004-637X .- 1538-4357. ; 865:2
-
Tidskriftsartikel (refereegranskat)abstract
- We report an orbital characterization of GJ1108Aab that is a low-mass binary system in the pre-main-sequence phase. Via the combination of astrometry using adaptive optics and radial velocity measurements, an eccentric orbital solution of e = 0.63 is obtained, which might be induced by the Kozai-Lidov mechanism with a widely separated GJ1108B system. Combined with several observed properties, we confirm that the system is indeed young. Columba is the most probable moving group, to which the GJ1108A system belongs, although its membership to the group has not been established. If the age of Columba is assumed for GJ1108A, the dynamical masses of both GJ1108Aa and GJ1108Ab (M-dynamical,M-GJ1108Aa= 0.72 +/- 0.04 M-circle dot and M-dynamical,M-GJ1108Ab = 0.30 +/- 0.03 M-circle dot) are more massive than what an evolutionary model predicts based on the age and luminosities. We consider that the discrepancy in mass comparison can be attributed to an age uncertainty; the system is likely older than stars in Columba, and effects that are not implemented in classical models such as accretion history and magnetic activity are not preferred to explain the mass discrepancy. We also discuss the performance of the evolutionary model by compiling similar low-mass objects in the evolutionary state based on the literature. Consequently, it is suggested that the current model on average reproduces the mass of resolved low-mass binaries without any significant offsets.
|
|
| 2. |
- Duran-Castells, C., et al.
(författare)
-
Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction
- 2023
-
Ingår i: Journal of Virology. - : American Society for Microbiology. - 0022-538X .- 1098-5514. ; 97:2
-
Tidskriftsartikel (refereegranskat)abstract
- Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control. The implementation and access to combined antiretroviral treatment (cART) have dramatically improved the quality of life of people living with HIV (PLWH). However, some comorbidities, such as neurological disorders associated with HIV infection still represent a serious clinical challenge. Soluble factors in plasma that are associated with control of HIV replication and neurological dysfunction could serve as early biomarkers and as new therapeutic targets for this comorbidity. We used a customized antibody array for determination of blood plasma factors in 40 untreated PLWH with different levels of viremia and found sirtuin-2 (SIRT2), an NAD-dependent deacetylase, to be strongly associated with elevated viral loads and HIV provirus levels, as well as with markers of neurological damage (a-synuclein [SNCA], brain-derived neurotrophic factor [BDNF], microtubule-associated protein tau [MAPT], and neurofilament light protein [NFL]). Also, longitudinal analysis in HIV-infected individuals with immediate (n = 9) or delayed initiation (n = 10) of cART revealed that after 1 year on cART, SIRT2 plasma levels differed between both groups and correlated inversely with brain orbitofrontal cortex involution. Furthermore, targeting SIRT2 with specific small-molecule inhibitors in in vitro systems using J-LAT A2 and primary glial cells led to diminished HIV replication and virus reactivation from latency. Our data thus identify SIRT2 as a novel biomarker of uncontrolled HIV infection, with potential impact on neurological dysfunction and offers a new therapeutic target for HIV treatment and cure.IMPORTANCE Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control. High plasma levels of sirtuin-2 (SIRT2), an NAD(+) deacetylase, were detected in uncontrolled HIV infection and were strongly associated with plasma viral load and proviral levels. In parallel, SIRT2 levels in the peripheral blood and CNS were associated with markers of neurological damage and brain involution and were more pronounced in individuals who initiated cART later in infection. In vitro infection experiments using specific SIRT2 inhibitors suggest that specific targeting of SIRT2 could offer new therapeutic treatment options for HIV infections and their associated neurological dysfunction.
|
|
| 3. |
|
|
| 4. |
- Grigoriadis, K., et al.
(författare)
-
Improving the recycling rate of the construction industry
- 2019
-
Ingår i: Sustainable Construction Materials and Technologies. - : International Committee of the SCMT conferences.
-
Konferensbidrag (refereegranskat)abstract
- Construction and Demolition Waste (CDW) accounts for approximately 25-30% of all waste generated across Europe each year. However, Waste Framework Directive 2008/98/EC requires from all EU member states to achieve at least 70% re-use, recycling or other recovery of non-hazardous CDW by 2020. In response, the Horizon 2020 RE4 Project (REuse and REcycling of CDW materials and structures in energy efficient pREfabricated elements for building REfurbishment and construction) consortium was set up. Its main aims are to assess the quality of various CDW fractions (e.g. mineral aggregate, timber, plastics, silt & clay), improve the quality of mineral aggregates and develop different building elements/components which contain at least 65% of CDW. Innovative building concepts will also be developed in an effort to improve recycling rates of future buildings through the use of prefabrication and modular design. The developed products and technologies will be assessed in a number of test sites by building 2-storey demonstration houses.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Whittaker, M. J., et al.
(författare)
-
Novel construction and demolition waste (CDW) treatment and uses to maximize reuse and recycling
- 2021
-
Ingår i: Advances in Building Energy Research. - : Taylor and Francis Ltd.. - 1751-2549 .- 1756-2201. ; 15:2, s. 253-269
-
Tidskriftsartikel (refereegranskat)abstract
- The EU Waste Framework Directive 2008/98/EC states that all member states should take all necessary measures in order to achieve at least 70% re-use, recycling or other recovery of non-hazardous Construction and Demolition Waste (CDW) by 2020. In response, the Horizon 2020 RE4 project consortium (REuse and REcycling of CDW materials and structures in energy efficient pREfabricated elements for building REfurbishment and construction) consisting of 12 research and industrial partners across Europe, plus a research partner from Taiwan, was set up. For its success, the approach of the Project was manifold, developing sorting technologies to first improve the quality of CDW-derived aggregate. Simultaneously, CDW streams were assessed for quality and novel applications developed for aggregate, timber and plastic waste in a variety of products including structural and non-structural elements. With all products considered, innovative building concepts have been designed in a bid to improve future reuse and recycling of the products by promoting prefabricated construction methods and modular design to ease future recycling and increase value of the construction industry. The developed technologies and products have been put to the test in different test sites in building a two-storey house containing at least 65% of CDW. © 2019, © 2019 The Author(s)..
|
|
